April 15 (Reuters) - Neumora Therapeutics said on Monday the U.S. Food and Drug Administration had placed a clinical hold on early-stage study of its experimental schizophrenia drug. (Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.5 USD | -0.11% | -1.55% | -44.28% |
05-14 | Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression | MT |
05-14 | Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.28% | 1.52B | |
+48.67% | 58.71B | |
-2.76% | 41.31B | |
+36.42% | 39.2B | |
-11.22% | 27.4B | |
+9.25% | 26.55B | |
-23.10% | 18.98B | |
+1.88% | 12.51B | |
+26.43% | 12.08B | |
+21.74% | 11.94B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- U.S. FDA places clinical hold on Neumora's schizophrenia drug study